# Phenotap

> Phenotap is a New York biosensing startup developing KetoTap Core, a patent-pending beta-hydroxybutyrate oxidase designed to make ketone test strips and continuous ketone monitors simpler, more stable and less expensive to manufacture. After initially presenting a non-invasive consumer monitor and personalized-nutrition platform, the company now positions itself as a B2B OEM enzyme supplier to established device makers.

- **Founded:** 2021
- **Headquarters:** New York, United States
- **Founders:** Giovanni Battistini (CEO & Co-Founder), Janet Tamada, Ph.D. (VP of Biosensing & Co-Founder), Joe Wang, Ph.D. (Chief Biosensing Scientist & Co-Founder)
- **Team size:** 2–10 employees; LinkedIn displayed five employees when researched
- **Products:** KetoTap Core, KetoTap, Cognizant Nutrition platform
- **Notable:** Engineered a patent-pending BHB oxidase intended to eliminate the external NAD+ co-factor and mediator required by conventional dehydrogenase sensing., Secured a $3 million, 18-month program-related investment from the Helmsley Charitable Trust in 2025., Built research and validation collaborations with UC Davis, UC San Diego, Codexis and EvoEnzyme.

## Products & services

- **KetoTap Core** — A patent-pending BHB oxidase intended as a drop-in sensing enzyme for blood-ketone strips, continuous ketone monitors and combined CGM-CKM devices. Phenotap says customer sampling is planned to begin in Q2 2026.
- **KetoTap** — The company’s earlier non-invasive continuous ketone-monitor concept, designed to send hourly beta-hydroxybutyrate trends to a smart device. It remains referenced in 2025 public material, while the current website centers KetoTap Core.
- **Cognizant Nutrition platform** — An earlier consumer-health concept pairing metabolic measurements with personalized diet and lifestyle insight; it is documented in Phenotap’s early research and third-party company profiles but is not the focus of the current company site.

## Achievements

- Engineered a patent-pending BHB oxidase intended to eliminate the external NAD+ co-factor and mediator required by conventional dehydrogenase sensing.
- Secured a $3 million, 18-month program-related investment from the Helmsley Charitable Trust in 2025.
- Built research and validation collaborations with UC Davis, UC San Diego, Codexis and EvoEnzyme.
- Filed the KETOTAP trademark for sensor, mobile-application and patient-monitoring uses in April 2022.
- Announced plans to scale production and begin customer sampling of KetoTap Core in Q2 2026.

## Latest updates

- **2024-09** — CEO Giovanni Battistini discussed Phenotap’s non-invasive ketone-monitor concept in a 47-minute FlavorWiki webcast.
- **2025-01** — UC Davis venture materials listed Phenotap at proof-of-concept/core-IP stage and raising seed funding.
- **2025-03** — The Helmsley Charitable Trust awarded Phenotap a $3 million, 18-month program-related investment for development of a BHB oxidase enabling continuous ketone sensing.
- **2025-07** — Phenotap and UC Davis publicly announced the Helmsley financing and described KetoTap Core as the route to more stable and scalable ketone sensing.
- **2026-06** — Battistini said Phenotap was preparing to sample its proprietary KetoTap Core enzyme after years of R&D collaboration.
- **2026-04** — Phenotap’s current plan calls for scaling production and beginning customer sampling in Q2 2026.

## Links

- Website: https://www.phenotap.com/
- LinkedIn: https://www.linkedin.com/company/phenotap

---

Profile page: https://yespress.io/phenotap
Published by YesPress — https://yespress.io
Last updated: 2026-08-22